| For: | Wishahi M. Treatment-induced neuroendocrine prostate cancer and de novo neuroendocrine prostate cancer: Identification, prognosis and survival, genetic and epigenetic factors. World J Clin Cases 2024; 12(13): 2143-2146 [PMID: 38808339 DOI: 10.12998/wjcc.v12.i13.2143] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v12/i13/2143.htm |
| Number | Citing Articles |
| 1 |
G. A. Kovchenko, A. V. Sivkov, L. N. Lyubchenko, A. D. Kaprin. Epigenetic abnormalities and neuroendocrine differentiation in prostate cancer. Siberian journal of oncology 2025; 24(1) doi: 10.21294/1814-4861-2025-24-1-115-124
|
| 2 |
Pampana Lakshmi, Jagrati Parashar, Biswajit Biswas, Ramesh Ummanni. Hypoxia‑induced miR‑135b‑5p promotes neuroendocrine differentiation of prostate cancer cells through HIF1AN‑HIF1α axis. Oncology Reports 2026; 55(4) doi: 10.3892/or.2026.9079
|
| 3 |
Sreyashi Bhattacharya, Nivedita Nag, Sandeep K. Singh, Kaustubh Datta, Samikshan Dutta. . Advances in Cancer Research 2026; doi: 10.1016/bs.acr.2026.07.003
|
| 4 |
Kazuki Iida, Kojiro Tashiro, Fumihiko Urabe, Yuya Matsui, Yusei Urabe, Takaaki Ishikawa, Juntaro Matsuzaki, Kentaro Yoshihara, Takahiro Kimura, Yoshimasa Saito. Large-scale Genomic Landscape and Clinical Outcomes of De Novo and Treatment-emergent Neuroendocrine Prostate Cancer. European Urology Open Science 2026; 90 doi: 10.1016/j.euros.2026.06.003
|
| 5 |
Lakshmi Kandhan L, Venkata Ramana Korrapati, Roshan Yedulla Reddy, Velmurugan Palaniyandi, Hariharasudhan Sekar, Sriram Krishnamoorthy. Salvage Re-transurethral Resection of Prostate as a Diagnostic and Therapeutic Bridge in Treatment-Emergent Neuroendocrine Prostate Cancer: A Multimodal Management Paradigm. Cureus 2026; doi: 10.7759/cureus.113696
|
| 6 |
Maoping Cai, Fengtao Zheng, Yang-Zi Ren, Chuqian Zhen, Dujiang Fu, Xian-Lu Song, Qing Li, Yuanyuan Qu, Zhe-Sheng Chen, Shan-Chao Zhao. New Insights into Potential Therapeutic Targets for Neuroendocrine Prostate Cancer: From Bench to Clinic. Research 2025; 8 doi: 10.34133/research.0791
|
| 7 |
Yong Wei, Jiang-Bo Sun, Qian-Ren-Shun Qiu, Yu-Xuan Zhao, Qing-Shui Zheng, Xiong-Lin Sun, Ning Xu, Xue-Yi Xue. A Neuroendocrine Differentiation-related Molecular Model for Prognosis Prediction in Prostate Cancer Patients. Current Medicinal Chemistry 2026; 33(12) doi: 10.2174/0109298673362568250505074520
|
| 8 |
Ilkay Tosun, Onur Sahin, İrem Güvendir Bakkaloğlu, Nurullah Mustafa Şişik, Melike Özçelik. Prognostic significance of neuroendocrine differentiation and PD-L1 expression in treatment-naïve prostate cancer. BMC Urology 2026; 26(1) doi: 10.1186/s12894-026-02053-0
|
| 9 |
Noora Lehtinen, Janne Suhonen, Rami Mäkelä, Antti Arjonen, Eetu Välimäki, Reetta Riikonen, Juha Kononen, Juha K. Rantala. Functional and molecular characterization of the first large cell neuroendocrine prostate cancer cell line. Current Molecular Pharmacology 2026; 19(1) doi: 10.1016/j.cmp.2026.07.001
|
| 10 |
Hossein Jadvar, Amir Iravani. Therapy strategies to defeat prostate cancer heterogeneity. Seminars in Nuclear Medicine 2026; 56(1) doi: 10.1053/j.semnuclmed.2025.11.025
|
| 11 |
Rahul Aggarwal, Sylvie Rottey, Alice Bernard-Tessier, Begoña Mellado, Takeo Kosaka, Walter M. Stadler, Lisa Horvath, Richard Greil, Bert O’Neil, Bilal A. Siddiqui, Thomas Bauernhofer, Mehmet A. Bilen, Ferry Eskens, Shahneen Sandhu, Crystal Shaw, Chia Hsin Ju, Benjamin E. Decato, Brian Yu, Ana Aparicio. Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study. Clinical Cancer Research 2025; 31(18) doi: 10.1158/1078-0432.CCR-25-1211
|
| 12 |
Wenwei Ying, Zhenshan Ding, Yuhui He, Jianfeng Wang, Xing Chen, Xuesong Li, Yanqing Gong. Surgery, radiotherapy and endocrine therapy for oligometastatic prostate cancer efficacy: a systematic review and network meta-analysis. PeerJ 2025; 13 doi: 10.7717/peerj.19819
|
| 13 |
Ziqin Wang, Hyeryeon Jung, Changhyeon Hong, Nancy Chen, Yunsol Jo, Issac Jung, Taeeun Kim, Gina Lee, Keaton Chien, Ming Chen, Jiaoti Huang, Jung Wook Park. RUNX1T1 drives stem-like small-cell neuroendocrine prostate cancer identity. Frontiers in Cell and Developmental Biology 2026; 14 doi: 10.3389/fcell.2026.1882758
|
| 14 |
Fakiha Firdaus, Osmel Companioni Napoles, Raul Ariel Dulce, Anusha Edupuganti, Surinder Kumar, Khushi Shah, Salih Salihoglu, Derek J. Van Booven, Richard Gasca, David B. Lombard, Joshua M. Hare, Fangliang Zhang, Rehana Qureshi, Himanshu Arora. Targeting endoplasmic reticulum stress and nitroso-redox imbalance in neuroendocrine prostate cancer: the therapeutic role of nitric oxide. Cell Death Discovery 2025; 11(1) doi: 10.1038/s41420-025-02774-5
|